Nasdaq · CIK 0001579428 · PHARMACEUTICAL PREPARATIONS
AXSOME THERAPEUTICS, INC.
AXSM chart by TradingView
PRICE HISTORY
LIVE · NASDAQAXSM chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $0.6B
- EBITDA
- $-0.2B
- FREE CASH FLOW
- $-0.1B
- EPS
- $-3.68
- GROSS MARGIN
- —
- ROIC
- 390.63%
Q1 FY26ENDED MAR 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 15 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
⤢
P / SALES (TTM)
12.2x
-35%10.4x18.8x
⤢
P / BOOK
158.5x
+61%11.3x158.5x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
12.1x
-30%10.2x17.2x
⤢
FCF YIELD (TTM)
-0.82%
+2.9pp-5.11%-0.82%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.2B
+2068%⤢
EBITDA (DERIVED)
$-0.1B
$0.0B⤢
NET INCOME
$-0.1B
$0.0B⤢
EPS (DILUTED)
$-1.26
$0.20⤢
REVENUE GROWTH YOY
57.42%
+78.1pp-20.70%86.65%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
-10.89%
+372.1pp-382.97%0.58%
⤢
RETURN ON CAPITAL
300.47%
+1189.9pp-889.47%3400.38%
⤢
RETURN ON EQUITY (TTM)
-344.96%
-285.9pp-523.02%-59.06%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN—
OPERATING MARGIN-33.14%
NET MARGIN-33.76%
FCF MARGIN-10.89%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$-0.0B
+$0.0B⤢
STOCK-BASED COMP
$0.0B
+131%⤢
CAPITAL EXPENDITURE
$0.0B
-50%⤢
SHARES OUTSTANDING
0.05B
+31%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.3B
+316%⤢
TOTAL DEBT
$0.2B
+101%⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 73.46%INSIDERS 15.35%OTHER / RETAIL 11.19%607 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 7.60% | 3.9M | $832.4M | -0.0% |
| Vanguard Portfolio Management LLC | 4.00% | 2.1M | $437.9M | NEW |
| Vanguard Capital Management LLC | 3.77% | 1.9M | $412.2M | NEW |
| FMR, LLC | 3.05% | 1.6M | $333.4M | +32.6% |
| Price (T.Rowe) Associates Inc | 2.56% | 1.3M | $280.2M | -12.8% |
| Invesco Ltd. | 2.52% | 1.3M | $276.1M | +1.9% |
| Geode Capital Management, LLC | 2.26% | 1.2M | $247.4M | +15.1% |
| Wellington Management Group, LLP | 2.23% | 1.1M | $243.7M | -6.3% |
| Deep Track Capital, Lp | 2.14% | 1.1M | $234.0M | -4.3% |
| State Street Corporation | 1.92% | 987K | $209.9M | +3.0% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.